If you have a certain kind of cancer, your doctor might suggest Retevmo as a treatment option for you. Retevmo is a prescription medication that’s used to treat certain kinds of the following cancers: ...

Retevmo (selpercatinib) is a brand-name drug prescribed for certain types of cancer in adults and some children. Retevmo comes as an oral capsule that’s typically taken twice per day, but the dosage ...

If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...

retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET). This ...

How about this for a label expansion? Two years after blessing Eli Lilly’s Retevmo to treat lung and thyroid cancers caused by a specific biomarker, the FDA has authorized the drug to be used across ...

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®. Treatment with Retevmo ...

Retevmo is an U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...

INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed ...

--Eli Lilly and Company today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors cabozantinib or vandetanib as an initial ...